Details
🚨 Medicine Supply Shortage Alert: Tegsedi® (inotersen)
The European Medicines Agency (EMA) has announced that Tegsedi® (inotersen) will become unavailable in the EU from the end of 2026.
Tegsedi® is used to treat hereditary transthyretin amyloidosis (hATTR) in adults with stage 1 or stage 2 nerve damage.